Elucidating the pathogenesis of demyelinating type of Guillain Barre syndrome.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07815
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 51030:Pathophysiologic neuroscience-related
• Research Institution: Chiba University
• Principal Investigator: Sawai Setsu 千葉大学, 医学部附属病院, 特任准教授 (10400962)
• Co-Investigator(Kenkyū-buntansha): 佐藤 守 千葉大学, 医学部附属病院, 特任准教授 (20401002) ; 桑原 聡 千葉大学, 大学院医学研究院, 教授 (70282481) ; 森 雅裕 千葉大学, 大学院医学研究院, 准教授 (70345023)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: ギラン・バレー症候群

Outline of Final Research Achievements

The aim of this study is to clarify that moesin is a target molecule for cytomegalovirus (CMV)-related Guillain-Barre syndrome (GBS). In an analysis using GBS multiple samples, anti-moesin antibodies also tested positive for demyelinating GBS other than CMV infection, suggesting a common pathology for demyelinating GBS. In the search for immune target sites in the moesin amino acid sequence using peptide array, two candidate peptides were found, and database analysis suggested molecular homology with CMV.

Free Research Field

神経免疫学

Academic Significance and Societal Importance of the Research Achievements

GBSの死亡率は約5％で、20％の患者は半年後に独立歩行ができない。このような現状から病態機序の解明が必要とされる。本研究によって得られた抗moesin抗体は脱髄型GBSの診断マーカーになる可能性があり、またmoesinは分子標的治療の新規治療法開発につながる可能性がある。